Ignite Creation Date:
2025-12-25 @ 1:44 AM
Ignite Modification Date:
2025-12-26 @ 4:57 AM
Study NCT ID:
NCT06999694
Status:
RECRUITING
Last Update Posted:
2025-09-10
First Post:
2025-05-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006528', 'term': 'Carcinoma, Hepatocellular'}], 'ancestors': [{'id': 'D000230', 'term': 'Adenocarcinoma'}, {'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008113', 'term': 'Liver Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D008107', 'term': 'Liver Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C520704', 'term': 'tremelimumab'}, {'id': 'C000613593', 'term': 'durvalumab'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 45}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2025-05-22', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-05', 'completionDateStruct': {'date': '2033-05-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-09-03', 'studyFirstSubmitDate': '2025-05-22', 'studyFirstSubmitQcDate': '2025-05-22', 'lastUpdatePostDateStruct': {'date': '2025-09-10', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2025-05-31', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2030-05-31', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Progression free survival', 'timeFrame': '12 months', 'description': 'Progression free survival is defined as the time from signing the informed consent to the first occurrence of disease progression or death from any cause (whichever occurs first) according to RECIST1.1'}], 'secondaryOutcomes': [{'measure': 'Local control', 'timeFrame': '12 months', 'description': 'Local control is defined as the time from signing the informed consent to the first occurrence of disease progression in the irradiated field according to RECIST1.1'}, {'measure': 'Time to progression', 'timeFrame': '12 months', 'description': 'Time to progression is defined as the time from signing the informed consent to the first occurrence of disease progression according to RECIST1.1'}, {'measure': 'Overall Response Rate', 'timeFrame': '12 months', 'description': 'Overall Response Rate is defined as a complete or partial response according to RECIST1.1'}, {'measure': 'Overall survival', 'timeFrame': '12 months', 'description': 'Overall survival is defined as the time from signing the informed consent to death from any cause.'}, {'measure': 'Incidence and severity of adverse events', 'timeFrame': '12 months', 'description': 'Adverse events will be graded using CTCAE v5'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['HCC - Hepatocellular Carcinoma', 'Durvalumab', 'Tremelimumab', 'Proton Radiotherapy']}, 'descriptionModule': {'briefSummary': 'Tremelimumab plus durvalumab (STRIDE regimen) is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC), yet it shows limited efficacy with an ORR of only 20.1%. Proton radiotherapy (RT), known for its precision and tissue-sparing advantages, has demonstrated improved survival outcomes and reduced toxicity compared to X-ray RT. Retrospective data suggest that combining proton RT with immune checkpoint inhibitors yields a promising ORR of 61.5%. Preclinical studies further support enhanced antitumor immunity when RT is combined with PD-L1 and CTLA-4 blockade. This phase II, single-arm clinical trial aims to evaluate the safety, efficacy, and immunologic effects of combining proton RT with tremelimumab and durvalumab in patients with unresectable HCC.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Participants must have diagnosis of HCC that is deemed unsuitable for surgical resection or transplant. Participants may have multiple lesions with a total maximal tumor dimension of \\< 20 cm, and no one lesion \\> 15 cm. Diagnosis should be confirmed by at least 1 criterion listed below:\n\n * Histologically or cytologically proven diagnosis of HCC.\n * Typical arterial enhancement and delayed washout on multiphasic CT or MRI.\n2. Age ≥18 years at the time of signing informed consent document.\n3. ECOG performance status 0-1.\n4. Barcelona Clinic Liver Cancer (BCLC) stages Intermediate (B) or Advanced (C).\n5. Child-Pugh score 5-6 liver function within 28 days of study registration.\n6. Documented virology status of hepatitis B virus (HBV), as confirmed by screening HBV serology test.\n7. Documented virology status of hepatitis C virus (HCV), as confirmed by screening HCV serology test.\n8. Ability to understand and the willingness to sign a written informed consent document\n9. Adequate bone marrow, liver, and renal function within 4 weeks before study registration\n\n * Hemoglobin ≥ 9.0 g/dL\n * Absolute neutrophil count (ANC) ≥ 1,000/mm3\n * Platelet count ≥ 50,000/μL\n * Total bilirubin \\< 2.5 mg/dL\n * Serum albumin \\>2.8 g/dL\n * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × upper limit of normal (ULN)\n * Prothrombin time ≤ 6 seconds prolonged\n * Serum creatinine ≤ 1.5 mg/dL\n\nExclusion Criteria:\n\n1. Prior invasive malignancy unless disease free for a minimum of 2 years\n2. Prior radiotherapy to the region of the liver that would result in overlap of radiation therapy fields\n3. Prior selective internal radiotherapy/hepatic arterial yttrium therapy, at any time\n4. Untreated active hepatitis B or hepatitis C\n5. Moderate to severe or intractable ascites\n6. Presence of distant metastases that cannot be encompassed by proton radiotherapy\n7. Untreated or incomplete treated esophageal or gastric varices\n8. Severe, active co-morbidity, defined as follows:\n\n * Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to registration\n * Myocardial infarction within the last 6 months prior to study entry\n * Acute bacterial or fungal infection requiring intravenous antibiotics within 28 days prior to study entry\n * A bleeding episode within 6 months prior to study entry due to any cause.\n * Thrombolytic therapy within 28 days prior to study entry.\n * Known bleeding or clotting disorder.\n * Uncontrolled psychotic disorder\n9. Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception\n10. Prior solid organ transplantation.\n11. Prior or active autoimmune disease (AID) including autoimmune hepatitis, inflammatory bowel disease, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogren's syndrome, Guillain-Barre syndrome, and multiple sclerosis.\n12. Prior or active thrombotic or bleeding disorders, hemoptysis, cerebral vascular accident, significant cardiac disease (ischemic or congestive heart failure), or gastrointestinal perforation.\n13. Inability to treat all sites of disease by proton radiotherapy (such as extrahepatic metastases or massive liver tumors whereby the liver constraints cannot be met for covering all sites of liver tumors using proton radiotherapy.)\n14. Known HIV infection."}, 'identificationModule': {'nctId': 'NCT06999694', 'acronym': 'Proton-STRIDE', 'briefTitle': 'Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC', 'organization': {'class': 'OTHER', 'fullName': 'Chang Gung Memorial Hospital'}, 'officialTitle': 'Proton Radiotherapy Combined With Tremelimumab and Durvalumab for BCLC Stage B and C Hepatocellular Carcinoma', 'orgStudyIdInfo': {'id': '202500583A3'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Proton radiotherapy combined with Tremelimumab and Durvalumab', 'description': 'Patients undergo proton radiotherapy combined with Tremelimumab and Durvalumab.', 'interventionNames': ['Radiation: Proton radiotherapy', 'Drug: Tremelimumab', 'Drug: Durvalumab']}], 'interventions': [{'name': 'Proton radiotherapy', 'type': 'RADIATION', 'description': '* 72.6 CGE in 22 fractions for tumors ≤1 cm from the hepatic hilum, bowel, and heart.\n* 66 CGE in 10 fractions for tumors \\>1 cm from the hepatic hilum, bowel, and heart.', 'armGroupLabels': ['Proton radiotherapy combined with Tremelimumab and Durvalumab']}, {'name': 'Tremelimumab', 'type': 'DRUG', 'otherNames': ['Imjudo'], 'description': 'Tremelimumab 300 mg will be administered as an IV infusion for one dose', 'armGroupLabels': ['Proton radiotherapy combined with Tremelimumab and Durvalumab']}, {'name': 'Durvalumab', 'type': 'DRUG', 'description': 'Durvalumab 1500 mg will be administered as an IV infusion every 4 weeks.\n\nTreatment Duration Guidelines:\n\n* Complete Response (CR): Patients who achieve a CR within one year of treatment will continue durvalumab for a total duration of two years.\n* Partial Response (PR): Patients who achieve a PR should continue durvalumab until achieving CR, disease progression (PD), or for a total duration of two years.\n* Stable Disease (SD): Patients with SD will receive duvalumab for a total of 6 doses.', 'armGroupLabels': ['Proton radiotherapy combined with Tremelimumab and Durvalumab']}]}, 'contactsLocationsModule': {'locations': [{'zip': '333', 'city': 'Taoyuan', 'state': 'Taiwan', 'status': 'RECRUITING', 'country': 'Taiwan', 'contacts': [{'name': 'Rodney Cheng-En Hsieh, MD, PhD', 'role': 'CONTACT', 'email': 'rodney445@gmail.com', 'phone': '+886-3-328-1200', 'phoneExt': '7000'}, {'name': 'Rodney Cheng En Hsieh, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Chang Gung Memorial Hospital at Linkou', 'geoPoint': {'lat': 24.99368, 'lon': 121.29696}}], 'centralContacts': [{'name': 'Rodney Cheng-En Hsieh, MD, PhD', 'role': 'CONTACT', 'email': 'rodney445@gmail.com', 'phone': '+88633281200', 'phoneExt': '7000'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO', 'description': 'Sharing individual participant data (IPD) with other researchers requires IRB review and approval. Presently, we do not have a plan to provide IPD to other researchers.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Chang Gung Memorial Hospital', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}